American Association for Cancer Research
Browse
00085472can142718-sup-137887_1_supp_2808311_nhq788.xls (142.5 kB)

Supplementary Table 2 from Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis

Download (142.5 kB)
dataset
posted on 2023-03-30, 23:25 authored by Alexey V. Sorokin, Binoj C. Nair, Yongkun Wei, Kathryn E. Aziz, Valentina Evdokimova, Mien-Chie Hung, Junjie Chen

Immunohistochemical expression of proPTPRN2 in invasive breast carcinoma specimens in National Cancer Institute Progression tumor microarrays.

History

ARTICLE ABSTRACT

The protein tyrosine phosphatase receptor PTPRN2 is expressed predominantly in endocrine and neuronal cells, where it functions in exocytosis. We found that its immature isoform proPTPRN2 is overexpressed in various cancers, including breast cancer. High proPTPRN2 expression was associated strongly with lymph node–positive breast cancer and poor clinical outcome. Loss of proPTPRN2 in breast cancer cells promoted apoptosis and blocked tumor formation in mice, whereas enforced expression of proPTPRN2 in nontransformed human mammary epithelial cells exerted a converse effect. Mechanistic investigations suggested that ProPTPRN2 elicited these effects through direct interaction with TRAF2, a hub scaffold protein for multiple kinase cascades, including ones that activate NF-κB. Overall, our results suggest PTPRN2 as a novel candidate biomarker and therapeutic target in breast cancer. Cancer Res; 75(9); 1846–58. ©2015 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC